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A B S T R A C T
A subepithelial mass is a common finding during endoscopic procedures. Endoscopic ultrasound (EUS) is an impor-
tant diagnostic modality in the evaluation of subepithelial lesions of the gastrointestinal tract. EUS is the diagnostic test
of choice to assess the size, margins, the layer of origin, echotexture, and to differentiate between an intramural and ex-
tramural lesion. However, the EUS imaging lacks the specificity. EUS-guided fine needle aspiration (EUS-FNA) or core
biopsy can help establish a tissue diagnosis and potentially characterize malignant risk. The aim of this article is to re-
view the diagnosis and management of the most common subepithelial gastric lesions with an emphasis on the role of en-
doscopic ultrasound.
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Introduction
Subepithelial mass lesions in the stomach, often re-
ferred to as submucosal lesions, although they may arise
from layers of the gastric wall other than histological
submucosa, are small, mostly asymptomatic lesions cov-
ered with normal mucosa incidentally found on endo-
scopic or radiological examinations1 (Figure 1). Occa-
sionally they may be large and outgrow their vascular
supply resulting in ulceration and bleeding. The differen-
tial diagnosis of these lesions ranges from clinically insig-
nificant to malignant conditions. Standard endoscopy
with biopsy is not reliable for providing diagnostic ma-
terial. Cross-sectional imaging techniques such as trans-
abdominal ultrasonography, computed tomography and
magnetic resonance are able to characterize the struc-
tures outside the gastric wall, but often fail to distin-
guish between the various causes of masses within the
gastric wall. Endoscopic ultrasonography (EUS) is cur-
rently the most effective method for differentiating be-
tween subepithelial lesions and wall impressions caused
by extramural protrusions2,3. EUS imaging of a subepi-
thelial lesion can provide us with information regarding
the size, margins, originating layer, internal echogeni-
city, echo pattern and vascular supply. Although these
endosonographic findings are helpful in categorization of
a lesion, they cannot absolutely determine the type of a
lesion or its benign or malignant nature. Based on the
clinical context, EUS-guided fine needle aspiration
(EUS-FNA) or core biopsy can help establish a tissue di-
agnosis and potentially characterize malignant risk4.
Epidemiology
Every endoscopist has encountered subepithelial le-
sions during endoscopy, but there are no reliable data on
their incidence, since the majority of cases remain
asymptomatic and undiagnosed. One retrospective study
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Fig. 1. Endoscopic view of the subepithelial gastric
lesion (GIST).
reported an incidence of 0.36% during upper endoscopies
in eight consecutive years5. The distribution of subepi-
thelial masses in the upper gastrointestinal tract is not
uniform – approximately 60% are found in the stomach,
30% in the esophagus and 10% in the duodenum6.
Endosonographic Characterization
of Subepithelial Lesions
Endosonography of the gastrointestinal tract wall at a
scanning frequency of 5–12 MHz typically exhibits five
distinct layers. Depending on the region of the gastroin-
testinal tract being examined and the frequency of the
ultrasound transducer (up to 20 MHz), nine layers can be
visualized7. The five layers seen on ultrasound images of
the normal gastrointestinal tract do not directly corre-
spond to the histological layers but approximate to: layer
1 – mucosal interface, layer 2 – muscularis mucosae,
layer 3 – submucosa plus the acoustical interface be-
tween the submucosa and muscularis propria, layer 4 –
muscularis propria minus the acoustical interface be-
tween the submucosa and muscularis propria, and layer
5 – serosa and subserosal fat8 (Figure 2). Extramural le-
sions cause compression to all five layers. Endosono-
graphic characterization of subepithelial lesions is based
on their: layer of origin, size, margins (smooth/irregular),
ehogenicity (anechoic, hypoechoic, hyperechoic, mixed),
texture (homogenous, inhomogeneous), presence of de-
fined internal structures (calcifications, strains, tubular
structures) and position towards neighboring structu-
res9. It is also possible to estimate blood perfusion by
Doppler imaging, visualize existing enlarged regional
lymph nodes, superficial hepatic focal lesions and free
peritoneal fluid. Numerous attempts have been made to
correlate specific endosonographic findings with histo-
pathological characteristics of certain lesions because
studies have shown that up to 20% of them may be
neoplastic10 (Table 1).
Hypoechoic lesions are clinically the most important
lesions within the gastric wall because of their malignant
potential. In the eight larger endosonographic studies
with histological controls, the following criteria were
markers of malignancy: irregular outline, presence of
echogenic or cystic internal structures, inhomogeneous
echo pattern, diameter exceeding 3–4 centimeters and
the presence of enlarged regional lymph nodes2,11–17.
However, correlation of EUS characterization and the fi-
nal pathology matches in only 77% of subepithelial le-
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TABLE 1
DIFFERENTIAL DIAGNOSIS OF INTRAMURAL SUBEPITHELIAL LESIONS BASED ON EUS FEATURES9,40
Type of lesion EUS layer EUS appearance
Benign
Leiomyoma 2, 3, 4 Hypoechoic, usually in the esophagus
Neurogenic tumors
Neuroma, schwannoma, ganglioneuroma
3 or 4 Hypoechoic
Lipoma 3 Hyperechoic, smooth margins
Cysts 3 Anechoic, compressible, 3–5 layer walls suggestive
of duplication cyst
Heterotopic pancreas 2 or 3 Hypoechoic or mixed echogenicity (ductal structures,
central cyst)
Granular cell tumor 2 or 3 Hypoechoic, smooth margins
Varices 3 Anechoic, perfusion visible
Lymphangioma 3 Anechoic, frequently polycystic, no perfusion
Malignant or with malignant potential
GIST 4 (rarely 2 or 3) Hypoechoic, bigger than 3 cm, irregular margins,
hyperechoic spots, disruption of EUS layers
Lymphoma 2, 3, 4 Hypoechoic
Carcinoid 2 or 3 Hypoechoic, smooth margins
Metastases Any Hypoechoic
Fig. 2. Normal five-layered gastric wall structure: 1) mucosal
interface, 2) muscularis mucosae, 3) submucosa, 4) muscularis
propria, 5) serosa.
sions6,14. If a subepithelial lesion is found to be a hypo-
echoic mass in the third or fourth echo layer on EUS,
tissue sampling should be strongly considered to estab-
lish the diagnosis. EUS-FNA, introduced in the early
1990s, is technically challenging and requires special
training. Accuracy is clearly operator dependent and cor-
relates with experience which is the reason why the early
studies presented with low sensitivity, specificity and
accuracy18. The yield of EUS-FNA in the diagnosis of
hypoechogenic masses may be improved by using immu-
no- cytochemical and immunocytogenetic analysis. Com-
mon markers are CD117 (c-kit), CD34, smooth muscle
actin and S10019. Growing experience with EUS-FNA
has increased a rate at which adequate specimens are
collected and the method is now approaching the diag-
nostic yield of EUS-FNA of pancreatic tumors and lymph
nodes which is around 85%20–22. EUS-guided core needle
biopsy using a 19-gauge Trucut needle as a method for
obtaining sufficient tissue for histological analysis gives
even wider range of diagnostic options than cytological
smears23,24. EUS-FNA is typically performed with 19 or
22-gauge needle directing it into the area of interest un-
der direct ultrasound guidance. Complications are rare
and include perforation, infection and hemorrhage. Ex-
ception is cyst aspiration where infection has been re-
ported in up to 15% of cases, which necessitates antibi-
otic prophylaxis18,25.
Malignant and Potentially Malignant
Subepthelial Lesions
Gastrointestinal stromal tumors (GIST)
GIST is the most commonly identified intramural
subepithelial lesions in the upper GI tract, with approxi-
mately two-thirds found in the stomach. According to the
recent classification, GISTs are defined as mesenchymal
spindle-cell, epitheloid or rarely pleomorphic tumors of
the GI tract which express Kit protein (stem cell factor
receptor protein – CD 117). These tumors originate from
CD 34-positive interstitial cells of Cajal, also known as
pacemaker cells of the GI tract26. Only the small subset
of GISTs (5%) is lacking the c-kit mutation. Approxi-
mately 10–30% of GISTs are malignant, although no
GIST can be definitively labeled as benign, because all
are considered to have some malignant potential26. Pa-
thological classification according to the size of the mass
and the mitotic count of the resected specimen stratifies
patients into »very low risk«, »low risk«, »intermediate
risk« and »high risk« groups for malignant behavior19.
EUS examination of a GIST shows a hypoechoic mass
with a homogenous echotexture arising from the second
or fourth EUS layer. Diameter bigger than 3 cm, irregu-
lar borders, cystic spaces and echogenous foci along with
enlarged adjacent lymph nodes suggest malignant growth,
although small tumors have been reported to meta-
stasize17,27 (Figure 3). There are only a few cytological
characteristics suggesting malignancy such as dominant
single cells or pleomorphic or hyperchromatic nuclei so
the cytological assessment of fine-needle aspirates is not
sufficient for determination of biologic behavior of
GISTs28. With immunohistochemical staining techniques
most GISTs are positive for c-kit (CD117). Those which
are negative should be considered for molecular analysis
for KIT or PDGFR mutations. It is also possible to
carry out mutational analysis of the KIT gene and prolif-
eration markers Ki-67 (MIB-1) which might be useful in
assessing the proliferative rate29,30.
Carcinoid tumor
Carcinoid tumors are neuroendocrine tumors that
originate from enterochromaffin-like cells. Gastric carci-
noids are being increasingly diagnosed and comprise 9%
of all carcinoid tumors31. Three types are recognized:
type 1 represents 65% of gastric carcinoids and is associ-
ated with atrophic gastritis and achlorhydria that accom-
pany antral G cell hyperplasia; lesions are often multiple
with low metastatic potential. Type 2 gastric carcinoids
develop in patients with Zollinger-Ellison syndrome due
to MEN-1 with small multiple lesions in the fundus and
body. Type 3 tumors are usually solitary and large lesions
that develop in normal gastric mucosa but display ag-
gressive local behavior and great potential for malig-
nancy and metastasis to local lymph nodes and liver (up
to 55%)32. Endoscopically carcinoids appear as polypoid
lesions with normal-appearing overlying mucosa. The
endosonographic appearance of carcinoids is usually of
an inhomogenous, hypoechoic lesion typically originat-
ing from the second or third EUS layer33 (Figure 4).
Management of type 3 carcinoids in a healthy individ-
ual is surgical resection34. Small type 1 and 2 carcinoids
(les than 1–2 cm) should be endoscopically resected, with
surveillance endoscopy at six-month intervals31.
Lymphoma
Primary gastric lymphomas are typically either dif-
fuse large B-cell lymphomas or low grade B-cell MALT
lymphomas, but disseminated nodal disease can second-
arily involve GI tract35. Endoscopically gastric lymphoma
can present as an ulcerated polypoid mass or thickening
of the gastric folds. Endosonographically it is presented
as a hypoechoic lesion localized in the second or the third
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Fig. 3. GIST of the stomach with endosonographic
characteristics of potential malignant growth.
layer, or extending through the entire wall (Figure 5).
EUS-FNA can be used to obtain tissue for flow cytometry
to establish the diagnosis1.
Benign Subepithelial Lesions
Lipomas
Lipomas are benign tumors composed of mature lipo-
cytes. They account for less than 1% of all intramural
gastric lesions36 They are tipically solitary lesions, endo-
scopically exhibit slightly yellow shimmering through
mucosa, with a pillow sign when probed with forceps36.
Endosonographically lipomas appear as intensely hy-
perechoic, well demarcated lesions located in the third
layer37 (Figure 6). Those characteristics make it possible
to diagnose a lipoma in most cases with no need in fur-
ther EUS follow up1. The incidentally found lipoma does
not require treatment, except for symptomatic lesion
which causes bleeding or obstruction.
Leiomyomas
Leiomyomas are benign gastrointestinal mesen-
chymal tumors with muscular differentiation. They are
rarely found in stomach, whereas in the esophagus they
are the most common subepithelial tumors. They arise
from the second or the fourth layer. Endosonographically
they appear as well demarcated, hypoechoic, sometimes
even anechoic lesions. On immunohistochemistry they
show positive staining for smooth muscle actin and des-
min and negative staining for CD117, CD34 and S1009.
Heterotopic pancreatic tissue
The term is used to describe ectopic pancreatic tissue
outside its normal location with no connection to the
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Fig. 4. Carcinoid of the gastric fundus. The endoscopic picture
shows a polypoid lesions with normal-appearing overlying mu-
cosa. The endosonographic picture shows inhomogenous,
hypoechoic lesion originating from the second layer. Fig. 5. Gastric MALT lymphoma presenting as an ulcerated
polypoid mass, endosonographically showing a hypoechoic
lesion extending through the entire wall.
Fig. 6. Lipoma arising from the gastric fundus, endosonogra-
phically appearing as a hyperechoic lesion originating from
the third layer.
pancreas. It is typically located in the gastric antrum,
and on endoscopy exhibit central umbilication. Endo-
sonographically they arise within the second or third
layer, appearing as a heterogeneous hypoechoic lesion
with poorly defined margins which may contain cystic
spaces, duct-like structures, hyperechoic spots and calci-
fications9 (Figure 7). Although the endosonographic find-
ings are so variable, they correlate well with histological
findings and along with typical endoscopic features, pan-
creatic heterotopia may be diagnosed with reasonable de-
gree of certainty38.
Duplication cyst
Duplication cysts result from an error in the embry-
onic development of the foregut causing invagination
and fusion of the longitudinal folds during embryonic de-
velopment. They are primarily diagnosed in the pediatric
population, in adults they are usually asymptomatic and
are more common in women, located either within or ad-
jacent to the GI wall.The diagnosis can be made with
EUS which will show an anechoic, smooth, spherical
structure with well defined wall39. There are only rare re-
ports of malignancy developing in duplication cysts40.
EUS FNA can aid in ruling out pancreatic pseudocyst or
pancreatic cystic neoplasm. In asymptomatic patients
observation alone is a reasonable option if the diagnosis
is certain41.
Management Strategies for
Subepithelial Lesions
All symptomatic tumors (pain, hemorrhage, obstruc-
tion, endocrine activity) require endoscopical or surgical
resection. Also, such treatment is required for all asymp-
tomatic lesions that meet any of the following criteria:
two or more of the endosonographic criteria for malig-
nancy (tumor size bigger than 30 mm, irregular outline,
inhomogeneous echostructure, not clearly defined layer
of origin with infiltrative growth, enlarged local lymph
nodes), development of symptoms during follow-up, sig-
nificant increase in size (more than 10 mm or more than
50% in diameter), changes in EUS appearance during fol-
low-up and cytological, histological, immunocytochemi-
cal, immunohistochemical or cytogenetic criteria of ma-
lignant or potentially malignant neoplasm1,9. EUS is
useful in assessing potential endoscopic resectability and
also in providing a surgeon with information about the
local topography, depth of infiltration and local lymph-
adenopathy. Generally, tumors that are smaller than 20
mm (30 mm in suitable locations) and not exceeding the
fourth layer are suitable for endoscopic resection.
Asymptomatic subepithelial lesions greater than 10
mm in diameter on EUS, unless the features of lipoma
are obviously present, require further evaluation that
should be put in the context of the availability of diagnos-
tic and therapeutic modalities, local expertise, individual
risk and patient’s preference42–44. Hypoechoic third and
fourth-layer lesions should undergo EUS-FNA and im-
munohystochemistry. If a diagnosis is not obtained, than
Trucut biopsy or endoscopic mucosal resection (for le-
sions not involving muscularis propria) can be consid-
ered. Endosonographic follow-up is an acceptable alter-
native to endoscopic resection in a subgroup of patients
with small hypoechoic and cystic lesions that meet cer-
tain criteria, which is in accordance to our unpublished
data. These are: size less than 30 mm, smooth outline,
homogenous texture, layer of origin clearly discernible
with no evidence of infiltrative growth, or local limph-
adenopathy, and no equivocal cytological or histological
criteria of malignancy on FNA. The suggested interval is
six months after the initial diagnosis, then six months
later, and then yearly afterwards1,9.
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ULOGA ENDOSKOPSKOG ULTRAZVUKA U EVALUACIJI SUBEPITELNIH LEZIJA U @ELUCU
S A @ E T A K
Subepitelni tumor, ili u literaturi ~e{}e spominjani termin »submukozni« tumor, je prominencija sluznice gastro-
intestinalnog sustava pokrivena normalnim epitelom koja se ~esto nalazi tijekom endoskopskih pretraga probavnog
trakta. Endoskopski ultrazvuk (EUZ) je zna~ajna dijagnosti~ka metoda u evaluaciji ovih lezija. EUZ-om je mogu}e
definirati da li se radi o intramuralnoj masi ili kompresiji izvana, procjeniti veli~inu i rubove lezije, ehoteksturu, vasku-
larizaciju, te odrediti sloj stjenke iz kojeg raste. Budu}i da EUZ nije dovoljno specifi~an u odre|ivanju etiologije subpi-
telnih lezija, tankoiglena aspiracija ili biopsija pod kontrolom EUZ-a mo`e nam pomo}i u postavljanju dijagnoze i odre-
|ivanja malignog potencijala. Cilj ovog ~lanka je pregled naj~e{}ih subepitelnih `elu~anih lezija, njihova dijagnostika i
terapija, s naglaskom na ulogu EUZ-a.
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